Synthesis and biological evaluation of new sulfonamide derivatives as potential anti-Trypanosoma cruzi agents. 2012

Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
Centro de Biotecnología Genómica, Instituto Politécnico Nacional, 88710, Reynosa, México.

Chagas disease continues to be one of the main parasitic diseases in Latin America. Despite the fact that it was discovered more than 100 years ago, no suitable pharmacologic treatment is available. We report the synthesis of new sulfonamidoquinoline and sulfonamides derivatives that were evaluated in vitro against two strains of Trypanosoma cruzi (NINOA and INC-5). Structure-activity relationship analysis indicated that small aromatic and large aromatic substituents on 4-aminoquinaldine increased trypanocidal activity on INC-5 and NINOA strains, respectively. Additionally, results show the importance of the sulfonamide group as a scaffold for the development of new anti-T. cruzi agents. Seven sulfonamide derivatives showed better lytic activity than nifurtimox and beznidazole against both strains of T. cruzi. N- (biphenyl-4-yl-sulfonyl)-nicotinamide (P-012) was established as the leader of the series for the development of more effective agents.

UI MeSH Term Description Entries
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D014344 Trypanocidal Agents Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. Trypanocidal Drugs,Trypanocides,Trypanosomicidal Agents,Trypanosomicides,Agents, Trypanocidal,Agents, Trypanosomicidal,Drugs, Trypanocidal
D014349 Trypanosoma cruzi The agent of South American trypanosomiasis or CHAGAS DISEASE. Its vertebrate hosts are man and various domestic and wild animals. Insects of several species are vectors. Trypanosoma cruzus,cruzi, Trypanosoma
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D060326 Chemistry Techniques, Synthetic Methods used for the chemical synthesis of compounds. Included under this heading are laboratory methods used to synthesize a variety of chemicals and drugs. Inorganic Synthesis,Inorganic Synthesis Methods,Inorganic Synthesis Techniques,Methods of Inorganic Synthesis,Methods of Organic Synthesis,Methods of Peptide Synthesis,Organic Synthesis,Organic Synthesis Methods,Organic Synthesis Techniques,Peptide Synthesis Methods,Peptide Synthesis Techniques,Peptide Synthesis, Synthetic,Synthetic Chemistry Techniques,Synthetic Peptide Synthesis,Chemistry Technique, Synthetic,Inorganic Syntheses,Inorganic Synthesis Method,Inorganic Synthesis Technique,Method, Inorganic Synthesis,Method, Organic Synthesis,Method, Peptide Synthesis,Methods, Inorganic Synthesis,Methods, Organic Synthesis,Methods, Peptide Synthesis,Organic Syntheses,Organic Synthesis Technique,Peptide Syntheses, Synthetic,Peptide Synthesis Method,Peptide Synthesis Technique,Syntheses, Inorganic,Syntheses, Organic,Syntheses, Synthetic Peptide,Synthesis Method, Inorganic,Synthesis Method, Peptide,Synthesis Methods, Inorganic,Synthesis Methods, Peptide,Synthesis Technique, Inorganic,Synthesis Technique, Organic,Synthesis Technique, Peptide,Synthesis Techniques, Inorganic,Synthesis Techniques, Organic,Synthesis Techniques, Peptide,Synthesis, Inorganic,Synthesis, Organic,Synthesis, Synthetic Peptide,Synthetic Chemistry Technique,Synthetic Peptide Syntheses,Technique, Inorganic Synthesis,Technique, Organic Synthesis,Technique, Peptide Synthesis,Technique, Synthetic Chemistry,Techniques, Inorganic Synthesis,Techniques, Organic Synthesis,Techniques, Peptide Synthesis,Techniques, Synthetic Chemistry
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
January 2017, Medicinal chemistry (Shariqah (United Arab Emirates)),
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
February 2009, Bioorganic & medicinal chemistry,
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
January 2019, Medicinal chemistry (Shariqah (United Arab Emirates)),
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
September 2012, European journal of medicinal chemistry,
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
December 2018, Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry,
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
March 2008, Bioorganic & medicinal chemistry,
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
May 2017, Acta poloniae pharmaceutica,
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
March 2022, Molecules (Basel, Switzerland),
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
January 2017, Current pharmaceutical design,
Virgilio Bocanegra-Garcia, and Juan Carlos Villalobos-Rocha, and Benjamin Nogueda-Torres, and Maria Edith Lemus-Hernandez, and Argelia Camargo-Ordonez, and Ninfa Maria Rosas-Garcia, and Gildardo Rivera
December 2011, Experimental parasitology,
Copied contents to your clipboard!